Rise Therapeutics Secures New Funding To Advance First-in-Class R-2487 Oral Immune Biomodulator Into Sjogren’s Disease Clinical Testing (Bio Space)
UF startup Rise Therapeutics, a clinical-stage biotechnology company developing a novel class of oral targeted immunotherapies, announced it will be initiating clinical evaluation of R-2487 in SjD.
Dose Escalation Completed for Rise Therapeutics’ R-3750 and R-2487 Clinical Trials
UF startup Rise Therapeutics, a clinical-stage biotechnology company developing novel oral immunotherapeutic medicines, announced that it has completed dose escalation enrollment stages for both its R-2487 and R-3750 clinical trials.